Home » Topics » Regulatory » NMPA

NMPA
RSS

Linzess approved in China for IBS with constipation

Jan. 16, 2019

Chinese NMPA accepts IND for Asceltis Pharma's third HCV drug ASC-21

Jan. 3, 2019

Tyvyt approved in China for the treatment of Hodgkin's lymphoma

Dec. 27, 2018

Toripalimab first domestically produced anti-PD-1 MAb approved in China

Dec. 20, 2018

China becomes first country to approve roxadustat

Dec. 18, 2018

China SFDA clears phase I trial of A-319 in B-cell malignancies

Nov. 13, 2018

Elunate approved in China for colorectal cancer

Sep. 5, 2018

CFDA approves INDs for Innovent's IBI-101 and IBI-307

July 27, 2018

Luye cleared for phase I trials in China with LY-03012

June 21, 2018

CFDA grants priority review to Pharnext's PXT-3003 for CMT1A

June 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...